Mosaic ImmunoEngineering (CPMV) Non Operating Investment Income (2010 - 2013)
Mosaic ImmunoEngineering (CPMV) posted quarterly Non Operating Investment Income of -$347.0 for Q4 2013, down 100.62% quarter-over-quarter from $55873.0 in Q3 2012.
Mosaic ImmunoEngineering (CPMV) Non Operating Investment Income (2010 - 2013) Analysis & Trends
Mosaic ImmunoEngineering's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$347.0 for Q4 2013.
- In Q4 2013, Non Operating Investment Income changed N/A year-over-year to -$347.0; the TTM figure through Nov 2014 stood at -$347.0 (changed 0.0% YoY), while the FY2018 annual figure was -$242615.0, down 121.0% from the prior year.
- Non Operating Investment Income for Q4 2013 stood at -$347.0, down from $55873.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $268394.0 in Q2 2012, with the low at -$648740.0 in Q3 2010.
- The 4-year median for Non Operating Investment Income is $40054.0 (2012), against an average of -$28271.6.
- The sharpest annual moves came in 2011 and 2012: Non Operating Investment Income jumped 106.01% in 2011, then decreased 16.31% in 2012.
- Mosaic ImmunoEngineering's Non Operating Investment Income stood at -$648740.0 in 2010, then surged by 106.01% to $39005.0 in 2011, then jumped by 43.25% to $55873.0 in 2012, then sank by 100.62% to -$347.0 in 2013.
- Business Quant data shows CPMV's Non Operating Investment Income at -$347.0 in Q4 2013, $55873.0 in Q3 2012, and $268394.0 in Q2 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -347.00 |
| Nov 30, 2013 | -347.00 |
| Aug 31, 2012 | 55,873.00 |
| Aug 31, 2012 | 55,873.00 |
| May 31, 2012 | 268,394.00 |
| May 31, 2012 | 268,394.00 |
| Feb 29, 2012 | 40,054.00 |
| Feb 29, 2012 | 40,054.00 |
| Aug 31, 2011 | 39,005.00 |
| Aug 31, 2011 | 39,005.00 |
| Feb 28, 2011 | 47,860.00 |
| Feb 28, 2011 | 47,860.00 |
| Aug 31, 2010 | -648,740.00 |
| Aug 31, 2010 | -648,740.00 |